TILT Biotherapeutics is the world’s leading company developing oncolytic immunotherapies to enable T-cell therapies for solid tumors. It is headquartered in Finland with a fully owned subsidiary in the United States.
TILT’s Origins
The company’s origins can be traced to an article on oncolytic viruses that TILT’s founder and CEO Akseli Hemminki, M.D., Ph.D. read in the late 1990s. Dr. Hemminki’s recognized that the potential of oncolytic viruses matched his desire to directly help people living with cancer. This led him to continue his education, conducting post-doctoral research in the United States on oncolytic viruses.
Dr. Hemminki then returned to the University of Helsinki in 2003 as a Resident in Oncology and Radiology. He was named Professor of Oncology in 2007 and ran a compassionate treatment program from 2007 to 2012 that treated 290 patients with 10 different oncolytic viruses.
Dr. Hemminki’s research team used patient observations and proof of concept data from these patients to confirm the pivotal role of immunity in combating cancer with oncolytic virus therapies.
TILT Biotherapeutics is Born
This significant insight led to the creation of TILT Biotherapeutics in 2013 and its pioneering, patented TILT® technology.
Since its inception, the company has carried its lead adenoviral immunotherapy candidate TILT-123 through Phase I trials with patients from around the world. The company’s programs, have included different Phase Ia and Phase Ib trials in solid tumors with TILT-123 in combination with cancer immunotherapies in Europe and the U.S.
TILT has built a pipeline of preclinical and clinical stage investigational cancer immunotherapies intended to treat solid tumors.
Looking to the Future
In 2026, with the aim to create an optimal operational and capital structure with international industry standards, TILT Biotherapeutics initiated a group-wide reorganization of its operations with a business transfer, demerger and a U.S. flip. The purpose is to separate TILT-123 related assets and liabilities from the early-stage pharmaceutical development business. A new entity, TiltBio Inc was created to drive the later-stage development of TILT-123.
The group continues to be open to collaborations with pharmaceutical companies, specifically in the context of enhancing the therapeutic efficacy of cancer immunotherapies in development by stimulating T cells. It is also looking to explore licensing agreements to support the commercialization of its pipeline.
Our Mission, Vision, and Values:
Mission: To invest in a new future in cancer treatment by developing cutting-edge oncolytic viral technologies that activate the immune system, offering hope to patients with limited treatment options.
Vision: A future where cancer patients have access to innovative, life-saving therapies, so they can live longer and live better.
Values:
- Investment in patients: Our commitment to delivering new therapies to patients in need drives everything we do.
- Interconnected success: We believe in the power of teamwork and shared knowledge to achieve our goals.
- Integrity: We uphold the highest ethical standards in our work and take responsibility for delivering on our promises to patients and the scientific community.
- Impact: We aim to continually push the limits of what’s possible and are dedicated to making a real difference in the fight against cancer.